CMG제약

058820KOSDAQ

48.5 / 100

Reference Date: 2026-10-23

Financial Score21.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CMG Pharmaceutical is a core subsidiary of Chabiotech Group, specializing in the R&D, production, and sales of pharmaceuticals and health functional foods. The company focuses on developing improved new drugs using its proprietary STARFILM Technology, which enables unique taste and stability in oral disintegrating films (ODF). It is expanding into high-growth sectors such as oncology, anti-aging, ophthalmology, and maternal and baby care, while also operating an animal pharmaceutical business through its subsidiaries to enhance shareholder value.

Number of Employees

206people

Average Salary

62.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.41Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-5.15Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼264.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 562Won52-week high 2,14052-week low 536

1-month return3.0Point

1m -1.23% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-10-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12
Neutral주식등의대량보유상황보고서(일반)2026-10-12
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12
Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제8회차)2026-10-12